GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype.
GD2
GD2 quantification
N-glycolyl GM3
dinutuximab
gangliosides
medulloblastoma
naxitamab
neuroblastoma
racotumomab
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Dec 2022
08 Dec 2022
Historique:
received:
08
11
2022
revised:
30
11
2022
accepted:
06
12
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
Neuroblastoma (NBL) and medulloblastoma (MB) are aggressive pediatric cancers which can benefit from therapies targeting gangliosides. Therefore, we compared the ganglioside profile of 9 MB and 14 NBL samples by thin layer chromatography and mass spectrometry. NBL had the highest expression of GD2 (median 0.54 nmol GD2/mg protein), and also expressed complex gangliosides. GD2-low samples expressed GD1a and were more differentiated. MB mainly expressed GD2 (median 0.032 nmol GD2/mg protein) or GM3. Four sonic hedgehog-activated (SHH) as well as one group 4 and one group 3 MBs were GD2-positive. Two group 3 MB samples were GD2-negative but GM3-positive. N-glycolyl neuraminic acid-containing GM3 was neither detected in NBL nor MB by mass spectrometry. Furthermore, a GD2-phenotype predicting two-gene signature (
Identifiants
pubmed: 36551537
pii: cancers14246051
doi: 10.3390/cancers14246051
pmc: PMC9775636
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : HI-TRON Mainz
ID : HITR-2021-14.
Organisme : Stiftung Kinderkrebsforschung Mainz foundation
ID : SKFM_01_2022
Références
Cell Immunol. 1992 Jan;139(1):18-29
pubmed: 1728965
J Nucl Med. 1991 May;32(5):769-76
pubmed: 1902508
Cancer Res. 2001 Jan 1;61(1):363-9
pubmed: 11196188
Nat Med. 2020 May;26(5):720-731
pubmed: 32341580
Int J Oncol. 1993 Nov;3(5):909-15
pubmed: 21573452
Front Immunol. 2022 Feb 21;13:817296
pubmed: 35265074
Pediatr Blood Cancer. 2018 Jan;65(1):
pubmed: 28940863
Front Cell Dev Biol. 2022 Jan 06;9:769580
pubmed: 35071226
Cancer. 1985 Dec 1;56(11):2640-6
pubmed: 4052940
Cancer Discov. 2020 May;10(5):702-723
pubmed: 32193224
Cancer Immunol Res. 2018 Apr;6(4):494-495
pubmed: 29610423
Cancer. 1994 Dec 1;74(11):3010-22
pubmed: 7954264
Cancer Cell. 2017 Jun 12;31(6):737-754.e6
pubmed: 28609654
Cancer Discov. 2021 Nov;11(11):2764-2779
pubmed: 34373263
Anticancer Res. 1999 Nov-Dec;19(6B):5349-54
pubmed: 10697560
Neuron. 2022 Sep 21;110(18):2916-2928
pubmed: 35985323
Pediatr Blood Cancer. 2004 Aug;43(2):120-5
pubmed: 15236277
J Natl Cancer Inst. 1987 Jan;78(1):45-54
pubmed: 3467129
J Clin Oncol. 2007 Dec 1;25(34):5465-70
pubmed: 18048828
Genome Biol. 2014;15(12):550
pubmed: 25516281
Expert Opin Biol Ther. 2016;16(4):573-8
pubmed: 26903265
J Lipid Res. 2008 Dec;49(12):2678-89
pubmed: 18703820
Nat Biotechnol. 2017 Apr 11;35(4):314-316
pubmed: 28398314
Lancet Oncol. 2017 Jul;18(7):958-971
pubmed: 28545823
MEDICC Rev. 2021 Jul-Oct;23(3-4):21-28
pubmed: 34516533
Target Oncol. 2016 Apr;11(2):247-53
pubmed: 26891967
Hepatology. 2010 May;51(5):1799-809
pubmed: 20432257
Neurotherapeutics. 2022 Oct;19(6):1733-1751
pubmed: 35859223
Patholog Res Int. 2012;2012:235418
pubmed: 22482082
Klin Padiatr. 2017 May;229(3):147-167
pubmed: 28561228
Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Sep;1865(9):158741
pubmed: 32474112
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Nat Rev Neurol. 2012 May 08;8(6):340-51
pubmed: 22565209
Clin Dev Immunol. 2011;2011:245181
pubmed: 21941577
Front Oncol. 2020 Jul 07;10:1000
pubmed: 32733795
Acta Neuropathol. 2012 Apr;123(4):465-72
pubmed: 22134537
Biochimie. 2001 Jul;83(7):623-34
pubmed: 11522391
Cancer Res. 1990 Dec 1;50(23):7444-9
pubmed: 2253195
Prog Mol Biol Transl Sci. 2018;156:241-263
pubmed: 29747816
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Lancet. 2007 Jun 23;369(9579):2106-20
pubmed: 17586306
Glycobiology. 2007 Jul;17(7):57R-74R
pubmed: 17307762
Cancer Immunol Res. 2018 Jan;6(1):36-46
pubmed: 29180536
Drugs Today (Barc). 2021 Nov;57(11):677-688
pubmed: 34821881
BioDrugs. 2003;17(3):155-67
pubmed: 12749752
Nature. 2019 Aug;572(7767):74-79
pubmed: 31341285
Cancer Res. 1992 Aug 15;52(16):4342-7
pubmed: 1643631
Pediatr Dev Pathol. 2018 Jul-Aug;21(4):355-362
pubmed: 29067879
Cells. 2019 Oct 26;8(11):
pubmed: 31717732
Biomedicines. 2020 May 30;8(6):
pubmed: 32486168
Nat Med. 2018 May;24(5):572-579
pubmed: 29662203
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Cancer Cell. 2022 Jan 10;40(1):53-69.e9
pubmed: 34971569
Biochim Biophys Acta. 1978 Feb 27;528(2):257-67
pubmed: 623779
Lung Cancer. 2022 Apr;166:135-142
pubmed: 35278766
ISRN Dermatol. 2011;2011:848909
pubmed: 22363862
Pediatr Blood Cancer. 2013 Jun;60(6):985-93
pubmed: 23255319
Am J Clin Pathol. 1991 Aug;96(2):248-52
pubmed: 1713742
Cancers (Basel). 2021 Jan 29;13(3):
pubmed: 33572900
Cancer. 2001 Aug 15;92(4):924-31
pubmed: 11550167
Cancers (Basel). 2022 Jun 26;14(13):
pubmed: 35804907
Acta Neuropathol. 1991;82(1):45-54
pubmed: 1659106
Hybridoma. 2000 Jun;19(3):241-7
pubmed: 10952412